Sio Capital Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Sio Capital Management’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-182,630	Closed	-$124K	–	82
2022 Q1	$124K	Hold	182,630	–	–	0.04%	63
2021 Q4	$422K	Hold	182,630	–	–	0.13%	62
2021 Q3	$836K	Hold	182,630	–	–	0.27%	53
2021 Q2	$811K	Buy	+182,630	New	+$929K	0.2%	67
2020 Q1	–	Sell	-125,836	Closed	-$906K	–	96
2019 Q4	$906K	Buy	125,836 +3,300	+3%	+$29.8K	0.22%	62
2019 Q3	$1.32M	Sell	122,536 -10,004	-8%	-$107K	0.43%	51
2019 Q2	$1.72M	Sell	132,540 -26,418	-17%	-$351K	0.42%	52
2019 Q1	$1.57M	Hold	158,958	–	–	0.42%	55
2018 Q4	$1.65M	Buy	+158,958	New	+$1.92M	0.6%	53

Other funds holding LOGC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sio Capital Management's LOGC Position: Q2 2022 in Review

Sio Capital Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2022, closing a stake of 182,630 shares — an estimated $124K sold.

Sio Capital Management first reported a position in LOGC in Q4 2018 and held it in 9 quarters. The position peaked at $1.72M in Q2 2019. 47 funds tracked by Wall St. Rank hold LOGC as of Q2 2022.

Sio Capital Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Sio Capital Management sold 182,630 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $124K.
Sio Capital Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Sio Capital Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.72M in Q2 2019.
47 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Sio Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.